In this video, Payal Shah, MD, of the Basser Center for BRCA at Penn Medicine, examines the pathology of triple-negative breast cancer and offers recent updates in chemotherapy and immunotherapy for women with stages II - IV disease, including the modified I-SPY2 clinical trial currently recruiting at Penn to examine the addition of pembrolizumab to chemotherapy, and a soon to open trial of carboplatin plus atezolizumab.
Related Links:
Enrolling Clinical Trials: Proton Radiotherapy for Accelerated Partial Breast Irradiation in Stage 0, I & II Breast Cancer
The Basser Center for BRCA on Twitter
Dr Shah's Penn Profile
Published
February 13, 2018
Created by
BROADCASTMED